Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury

Sabry Ayad; John F Neylan; Tracy J Mayne; Deborah Gouveia; Madhav Swaminathan

doi:10.1016/j.ekir.2020.09.031

Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury

Kidney Int Rep. 2020 Sep 25;5(12):2325-2332. doi: 10.1016/j.ekir.2020.09.031. eCollection 2020 Dec.

Authors

Sabry Ayad¹, John F Neylan², Tracy J Mayne², Deborah Gouveia², Madhav Swaminathan³

Affiliations

¹ Cleveland Clinic, Anesthesiology Institute, Outcomes Research, Cleveland, Ohio, USA.
² Angion Biomedica Corporation, Uniondale, New York, USA.
³ Duke University, Durham, North Carolina, USA.

Abstract

Introduction: Nearly one-third of patients undergoing cardiac surgery involving cardiopulmonary bypass (CPB) experience cardiac surgery-associated (CSA) acute kidney injury (AKI); 5% require renal replacement therapy. ANG-3777 is a hepatocyte growth factor mimetic. In vitro, ANG-3777 reduces apoptosis and increases cell proliferation, migration, morphogenesis, and angiogenesis in injured kidneys. In animal models, ANG-3777 mitigates the effects of renal damage secondary to ischemia reperfusion injury and nephrotoxic chemicals. Phase 2 data in AKI of renal transplantation have shown improved renal function and comparable safety relative to placebo. The Guard Against Renal Damage (GUARD) study is a phase 2 proof of concept trial of ANG-3777 in CSA-AKI.

Methods: GUARD is a 240-patient, multicenter, double-blind, randomized placebo-controlled trial to assess the efficacy and safety of ANG-3777 in patients at elevated pre-surgery risk for AKI undergoing coronary artery bypass graft (CABG) or heart valve repair/replacement requiring CPB. Subjects are randomized 1:1 to receive ANG-3777 (2 mg/kg) or placebo. Study drug is dosed via 4 daily intravenous 30-minute infusions. The first dose is administered less than 4 hours after completing CPB, second at 24 ± 2 hours post-CPB, with two subsequent doses at 24 ± 2 hours after the previous dose.

Results: The primary efficacy endpoint is percent change from baseline serum creatinine to mean area under the curve from days 2 through 6. Secondary endpoints include change in estimated glomerular filtration rate from baseline to day 30, the proportion of patients diagnosed with AKI by stage through day 5, and the length of CSA-AKI hospitalization. Safety will include adverse events and laboratory measures.

Conclusion: This phase 2 study of ANG-3777 provides data to develop a phase 3 registrational study in this medically complex condition.

Keywords: ANG-3777; acute kidney injury; cardiac surgery; cardiopulmonary bypass; clinical trial; hepatocyte growth factor.